Cover Image

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

The purpose of this prospective multicenter phase 2 trial was to investigate the long-term outcome of reduced-intensity conditioning allogeneic stem cell transplantation (alloSCT) in patients with poor-risk chronic lymphocytic leukemia. Conditioning was fludarabine/ cyclophosphamide-based. Longitudi...

Full description

Saved in:
Bibliographic Details
Main Authors: Dreger, Peter (Author) , Döhner, Hartmut (Author) , Ritgen, Matthias (Author) , Böttcher, Sebastian (Author) , Busch, Raymonde (Author) , Dietrich, Sascha (Author) , Bunjes, Donald (Author) , Cohen, Sandra (Author) , Schubert, Jörg (Author) , Hegenbart, Ute (Author) , Beelen, Dietrich (Author) , Zeis, Matthias (Author) , Stadler, Michael (Author) , Hasenkamp, Justin (Author) , Uharek, Lutz (Author) , Scheid, Christof (Author) , Humpe, Andreas (Author) , Zenz, Thorsten (Author) , Winkler, Dirk (Author) , Hallek, Michael (Author) , Kneba, Michael (Author) , Schmitz, Norbert (Author) , Stilgenbauer, Stephan (Author)
Format: Article (Journal)
Language:English
Published: July 1, 2010
In: Blood
Year: 2010, Volume: 116, Issue: 14, Pages: 2438-2447
ISSN:1528-0020
DOI:10.1182/blood-2010-03-275420
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2010-03-275420
Get full text
Author Notes:Peter Dreger, Hartmut Döhner, Matthias Ritgen, Sebastian Böttcher, Raymonde Busch, Sascha Dietrich, Donald Bunjes, Sandra Cohen, Jörg Schubert, Ute Hegenbart, Dietrich Beelen, Matthias Zeis, Michael Stadler, Justin Hasenkamp, Lutz Uharek, Christof Scheid, Andreas Humpe, Thorsten Zenz, Dirk Winkler, Michael Hallek, Michael Kneba, Norbert Schmitz, and Stephan Stilgenbauer, for the German CLL Study Group
Description
Summary:The purpose of this prospective multicenter phase 2 trial was to investigate the long-term outcome of reduced-intensity conditioning allogeneic stem cell transplantation (alloSCT) in patients with poor-risk chronic lymphocytic leukemia. Conditioning was fludarabine/ cyclophosphamide-based. Longitudinal quantitative monitoring of minimal residual disease (MRD) was performed centrally by MRD-flow or real-time quantitative polymerase chain reaction. One hundred eligible patients were enrolled, and 90 patients proceeded to alloSCT. With a median follow-up of 46 months (7-102 months), 4-year nonrelapse mortality, event-free survival (EFS) and overall survival (OS) were 23%, 42%, and 65%, respectively. Of 52 patients with MRD monitoring available, 27 (52%) were alive and MRD negative at 12 months after transplant. Four-year EFS of this subset was 89% with all event-free patients except for 2 being MRD negative at the most recent assessment. EFS was similar for all genetic subsets, including 17p deletion (17p−). In multivariate analyses, uncontrolled disease at alloSCT and in vivo T-cell depletion with alemtuzumab, but not 17p−, previous purine analogue refractoriness, or donor source (human leukocyte antigen-identical siblings or unrelated donors) had an adverse impact on EFS and OS. In conclusion, alloSCT for poor-risk chronic lymphocytic leukemia can result in long-term MRD-negative survival in up to one-half of the patients independent of the underlying genomic risk profile. This trial is registered at http://clinicaltrials.gov as NCT00281983.
Item Description:Gesehen am 16.02.2023
Physical Description:Online Resource
ISSN:1528-0020
DOI:10.1182/blood-2010-03-275420

Similar Items